東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Identification of a Bifunctional HBV...

Bradley, Daniel P.,

FindBook

Google Book

Amazon

博客來

Identification of a Bifunctional HBV RNaseH-Capsid Inhibitor and Mechanistic Analysis of Cytotoxicity of α-Hydroxytroplone HBV-RNaseH Inhibitors /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Identification of a Bifunctional HBV RNaseH-Capsid Inhibitor and Mechanistic Analysis of Cytotoxicity of α-Hydroxytroplone HBV-RNaseH Inhibitors // Daniel P Bradley.
作者:	Bradley, Daniel P.,
面頁冊數:	1 electronic resource (171 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-01, Section: B.
Contained By:	Dissertations Abstracts International86-01B.
標題:	Virology. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31331792
ISBN:	9798383284285

Identification of a Bifunctional HBV RNaseH-Capsid Inhibitor and Mechanistic Analysis of Cytotoxicity of α-Hydroxytroplone HBV-RNaseH Inhibitors /
Bradley, Daniel P.,

Identification of a Bifunctional HBV RNaseH-Capsid Inhibitor and Mechanistic Analysis of Cytotoxicity of α-Hydroxytroplone HBV-RNaseH Inhibitors /Daniel P Bradley. - 1 electronic resource (171 pages)

Source: Dissertations Abstracts International, Volume: 86-01, Section: B.

Heptatits B virus (HBV) is a global pathogen that chronically infects >250 million people. HBV replicates by protein primed reverse transcription by a unique mechanism mediated by the viral polymerase (P) protein. P has evaded structural analysis for decades, despite being the target for antiviral therapies. Using the algorithmic protein folding prediction software AlphaFold2, we generated and validated a three-dimensional model of P, which provided unique insight to the confirmation of the Terminal Protein (TP) and priming of viral replication. The model of P further demonstrated utility for mechanistic analysis and in silico docking of replication inhibitors. Current antiviral therapies include nulceos(t)ide analogs that effectively suppress HBV replication but are not curative, therefore new therapies with unique mechanisms of action are needed to cure HBV. The Tavis lab has developed potent antivirals that target the ribonuclease H (RNaseH) activity of P and block viral replication with nanomolar efficacy. Preclinical analysis and development are ongoing, concurrently we have been evaluating the cellular effects and antiviral activities of HBV RNaseH inhibitors to inform our drug development efforts. Our analysis has identified a reactive oxygen species (ROS) dependent mechanism of cytotoxicity for the alpha-hydroxytropolone class of HBV RNaseH inhibitors, identifying a potential safety concern before in vivo studies. Separately, our evaluation of the antiviral activities of HBV RNaseH inhibitors identified a chemotype of bifunctional compounds that decrease capsid accumulation. HBV capsids are proteinaceous shells that assemble around the pre-genomic RNA (pgRNA), forming nucleocapsids. Capsids also self-assemble into genome-free or 'empty' capsids in excess compared to nucleocapsids. By measuring intracellular capsid accumulation, we identified the N-hydroxypyridinediones (HPD) chemotype of HBV RNaseH inhibitors as possessing novel capsid accumulation modulator (CAM) activities. The representative HPD 1466 inhibited empty capsid accumulation independent of viral replication and inhibited biochemical capsid assembly reactions with purified capsid protein. We conclude that the bimodal HPD HBV RNaseH inhibitor 1466 is the prototypic member of a new class of CAM (CAM-I) that inhibits capsid assembly rather than accelerating it as do all other CAM classes. These results lay the foundation for the identification of novel HBV core protein targeting antivirals.

English

ISBN: 9798383284285Subjects--Topical Terms:

642304
Virology.
Subjects--Index Terms:

Capsid assembly modulator

Identification of a Bifunctional HBV RNaseH-Capsid Inhibitor and Mechanistic Analysis of Cytotoxicity of α-Hydroxytroplone HBV-RNaseH Inhibitors /
LDR:03985nmm a22004213i 4500 001 2437519
005 20251124054757.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798383284285
035 $a (MiAaPQD)AAI31331792
035 $a AAI31331792
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Bradley, Daniel P., $e author. $3 3828529
245 1 0 $a Identification of a Bifunctional HBV RNaseH-Capsid Inhibitor and Mechanistic Analysis of Cytotoxicity of α-Hydroxytroplone HBV-RNaseH Inhibitors / $c Daniel P Bradley.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (171 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-01, Section: B.
500 $a Advisors: Tavis, John E. Committee members: DiPaolo, Richard J.; Tse, Long Ping Victor.
502 $b Ph.D. $c Saint Louis University $d 2024.
520 $a Heptatits B virus (HBV) is a global pathogen that chronically infects >250 million people. HBV replicates by protein primed reverse transcription by a unique mechanism mediated by the viral polymerase (P) protein. P has evaded structural analysis for decades, despite being the target for antiviral therapies. Using the algorithmic protein folding prediction software AlphaFold2, we generated and validated a three-dimensional model of P, which provided unique insight to the confirmation of the Terminal Protein (TP) and priming of viral replication. The model of P further demonstrated utility for mechanistic analysis and in silico docking of replication inhibitors. Current antiviral therapies include nulceos(t)ide analogs that effectively suppress HBV replication but are not curative, therefore new therapies with unique mechanisms of action are needed to cure HBV. The Tavis lab has developed potent antivirals that target the ribonuclease H (RNaseH) activity of P and block viral replication with nanomolar efficacy. Preclinical analysis and development are ongoing, concurrently we have been evaluating the cellular effects and antiviral activities of HBV RNaseH inhibitors to inform our drug development efforts. Our analysis has identified a reactive oxygen species (ROS) dependent mechanism of cytotoxicity for the alpha-hydroxytropolone class of HBV RNaseH inhibitors, identifying a potential safety concern before in vivo studies. Separately, our evaluation of the antiviral activities of HBV RNaseH inhibitors identified a chemotype of bifunctional compounds that decrease capsid accumulation. HBV capsids are proteinaceous shells that assemble around the pre-genomic RNA (pgRNA), forming nucleocapsids. Capsids also self-assemble into genome-free or 'empty' capsids in excess compared to nucleocapsids. By measuring intracellular capsid accumulation, we identified the N-hydroxypyridinediones (HPD) chemotype of HBV RNaseH inhibitors as possessing novel capsid accumulation modulator (CAM) activities. The representative HPD 1466 inhibited empty capsid accumulation independent of viral replication and inhibited biochemical capsid assembly reactions with purified capsid protein. We conclude that the bimodal HPD HBV RNaseH inhibitor 1466 is the prototypic member of a new class of CAM (CAM-I) that inhibits capsid assembly rather than accelerating it as do all other CAM classes. These results lay the foundation for the identification of novel HBV core protein targeting antivirals.
546 $a English
590 $a School code: 0193
650 4 $a Virology. $3 642304
650 4 $a Molecular biology. $3 517296
650 4 $a Cellular biology. $3 3172791
653 $a Capsid assembly modulator
653 $a HBV polymerase
653 $a Hepatitis B virus
653 $a RNaseH inhibitor
690 $a 0720
690 $a 0307
690 $a 0379
710 2 $a Saint Louis University. $b Microbiology. $e degree granting institution. $3 3819017
720 1 $a Tavis, John E. $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-01B.
790 $a 0193
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31331792